Arcadia Biosciences, Inc. short interest in 2018
In 2018, Arcadia Biosciences, Inc.'s disclosed short interest ran from 0.90% of shares outstanding on 12 Jan 2018 to 7.27% on 31 Dec 2018, a change of +6.37 percentage points. The year's high was 20.85% on 31 May 2018 and its low 0.90% on 12 Jan 2018, averaging 8.32% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.53 days on 30 Nov 2018. Full history: Arcadia Biosciences, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2018 in figures
- Start of year
- 0.90% (12 Jan 2018)
- End of year
- 7.27% (31 Dec 2018)
- Change
- +6.37 pp
- High
- 20.85% (31 May 2018)
- Low
- 0.90% (12 Jan 2018)
- Average
- 8.32%
- Highest days to cover
- 7.53 (30 Nov 2018)
- SEC filings marked
- 8
Every report in 2018
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2018 | 0.90% | 1.00 | |
| 15 Mar 2018 | 4.01% | 1.00 | |
| 29 Mar 2018 | 8.90% | 1.00 | 10-K filed, results (8-K) |
| 13 Apr 2018 | 8.07% | 1.00 | |
| 30 Apr 2018 | 5.51% | 1.00 | |
| 15 May 2018 | 11.20% | 1.00 | 10-Q filed, results (8-K) |
| 31 May 2018 | 20.85% | 1.00 | |
| 15 Jun 2018 | 8.38% | 1.00 | |
| 13 Jul 2018 | 17.64% | 2.66 | |
| 31 Jul 2018 | 8.93% | 1.00 | |
| 15 Aug 2018 | 8.77% | 2.87 | 10-Q filed, results (8-K) |
| 31 Aug 2018 | 8.57% | 3.32 | |
| 14 Sep 2018 | 7.81% | 1.74 | |
| 28 Sep 2018 | 6.09% | 4.38 | |
| 15 Oct 2018 | 6.19% | 1.59 | |
| 31 Oct 2018 | 6.78% | 2.30 | |
| 15 Nov 2018 | 6.99% | 3.35 | 10-Q filed, results (8-K) |
| 30 Nov 2018 | 6.40% | 7.53 | |
| 14 Dec 2018 | 7.05% | 1.69 | |
| 31 Dec 2018 | 7.27% | 1.88 |
See also: Arcadia Biosciences, Inc.'s full history · most shorted US stocks of 2018 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.